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Abstract
Background: Allergic and non-allergic rhinitis cause a lot of symptoms in everyday life. To decrease the burden
more information of the preventable risk factors is needed. We assessed prevalence and risk factors for chronic
nasal symptoms, exploring the effects of smoking, environmental tobacco smoke, exposure to occupational irritants,
and their combinations.
Methods: In 2016, a postal survey was conducted among a random population sample of 8000 adults in Helsinki,
Finland with a 50.5% response rate.
Results: Smoking was associated with a significant increase in occurrence of chronic rhinitis (longstanding nasal
congestion or runny nose), but not with self-reported or physician diagnosed allergic rhinitis. The highest
prevalence estimates of nasal symptoms, 55.1% for chronic rhinitis, 49.1% for nasal congestion, and 40.7% for runny
nose, were found among smokers with occupational exposure to gases, fumes or dusts.
Besides active smoking, also exposure to environmental tobacco smoke combined with occupational exposure
increased the risk of nasal symptoms.
Conclusions: Smoking, environmental tobacco smoke, and occupational irritants are significant risk factors for nasal
symptoms with an additive pattern. The findings suggest that these factors should be systematically inquired in
patients with nasal symptoms for appropriate preventive measures. (192 words).
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Background
It is estimated that 500 million people worldwide suffer
from allergic rhinitis and in addition 200 million from
non-allergic rhinitis [1, 2]]. These conditions render a
considerable burden on both the patients and society in
terms of life quality, disability and costs [3–5].
Allergic rhinitis is considered to be part of a systemic al-
lergic condition often with comorbidities [6]. Rhinitis is a
risk factor for asthma and eczema [7–9], and affects
asthma and COPD control [10, 11]. Non-allergic rhinitis
is a heterogenous group of conditions with variable eti-
ology, e.g. hormonal, drug-induced, irritatative or idio-
pathic [2].
Rhinitis symptoms and chronic rhinosinusitis are signifi-
cantly more common among smoking individuals than
among non-smokers [12] . Smoking is also associated with
the development of nasal polyposis [13]. The harmful effects
of environmental tobacco smoke are also known from previ-
ous studies [14–17]. Occupational exposure to gases, dusts
or fumes is a risk factor for rhinitis and sinusitis [16, 18] as
well as for asthma and COPD [19], and eczema [9] . The
combined effects of smoking, environmental tobacco smoke
and occupational irritants on nasal symptoms have been less
well estimated.
The FinEsS study is a Nordic joint project on the
occurrence and risk factors of respiratory conditions in
Finland, Estonia and Sweden. The present study
assessed the prevalence of nasal symptoms and their as-
sociation with smoking, environmental tobacco smoke,* Correspondence: hanna.hisinger-molkanen@fimnet.fi
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and occupational irritants in a population based cohort
of 8000 Finnish adults.
Methods
Study population
In 2016, a postal questionnaire was mailed to a ran-
domly selected sample of 8000 adults aged 20–69 years
in 10-year age cohorts corresponding the gender and
age distribution of the Finnish population. The genders
were randomized separately. The sample was obtained
from the Finnish National Population Registry (permis-
sion Dnro 254/410/15; 8.1.2015).
The invited individuals were given the possibility to re-
spond either by mail or on the internet. Reminders were
sent twice. The questionnaire was mailed in Finnish,
Swedish or English, depending on the individuals` lan-
guage. Of the 8000 selected, 17 refused to participate, 7
mailed an empty questionnaire and one had died. Of the
7975 invited 4026 (50.5%) responded. Twenty-eight
questionnaires were excluded because they were not ad-
equately fulfilled. For the present analysis, 510 individ-
uals of the whole study population were excluded,
because the questions about smoking habits, environ-
mental tobacco smoke or exposure to gases, dusts or
fumes at work were not answered. Thus, the final sam-
ple included 3488 individuals (1997, 57.3% women;
1491, 42.7% men).
The study was approved by the Coordinating Ethics
Committee of Helsinki and Uusimaa Hospital District
(200/13/03/00/2015).
Questionnaire
In Helsinki, previous postal surveys were conducted in
1996 and 2006 [17]. In 2016 we used the same question-
naire as in 1996 and 2006, but also additional questions
about occupational and environmental exposure, nasal
symptoms and allergy were included.
Questions and definitions
Chronic rhinitis. A positive answer to either having long-
standing nasal congestion or runny nose or both.
Nasal congestion. Have you had longstanding nasal
congestion?
Runny nose. Have you had longstanding rhinitis?
Self-reported allergic rhinitis. Do you have now or have
you had previously allergic rhinitis (e.g. hay fever) or al-
lergic eye symptoms?
Physician diagnosed allergic rhinitis. Have you been di-
agnosed by a doctor as having allergic rhinitis?
Smoker. Current smoker or having stopped smoking
during the last year.
Ex-smoker. Stopped smoking more than 12 months
prior to the study.
Non-smoker. Neither current smoker nor ex-smoker.
Exposure to tobacco smoke at work. Are you now or
have you been heavily exposed to tobacco smoke at
work?
Exposure to tobacco smoke at home. Are you now or
have you been heavily exposed to tobacco smoke at
home?
Exposure to environmental tobacco smoke. A positive
answer to either exposure to tobacco smoke at work or
at home.
Exposure to gases, dusts or fumes at work (occupa-
tional irritants). Are you now or have you been heavily
exposed to gases, dusts or fumes at work?
Statistical analysis
All analyses were performed using SPSS version 23.0.
Comparisons of proportions were tested with the Mann-
Whitney U-test. p < 0.05 was regarded as statistically sig-
nificant. Multiple logistic regression models were per-
formed using smoking, exposure to tobacco smoke, and
exposure to gases, dusts or fumes at work as risk factors
for chronic nasal symptoms. Odds ratios (ORs) are pre-
sented with 95% confidence intervals (95%CI).
Results
The characteristics of the study population are shown in
Table 1. In total, 26.6% of the responders were smokers,
and 26% ex-smokers. Smoking was more common
among younger individuals, 31.6% of the responders
aged 20–29 years were smokers compared to 21.4% of
those aged 60–69 years (p = 0.00). Exposure to gases,
dusts or fumes was reported by 26.8% of the responders.
Exposure to these irritants was slightly less frequent
among younger individuals, 24.7% of those aged 20–
29 years had been exposed compared to 28.6% of those
aged 60–69 years (p = 0.068).
In the whole study sample, prevalence of chronic rhin-
itis (longstanding nasal congestion or runny nose) was
36.9%, of nasal congestion 29.8%, and of runny nose
27.9%. Smoking, environmental tobacco smoke and oc-
cupational irritants increased the prevalence in an addi-
tive manner (Fig. 1, Table 2). Smoking alone increased
slightly the nasal symptoms, but was not associated with
self-reported allergic rhinitis or physician-diagnosed al-
lergic rhinitis. However, if a smoker was also exposed to
occupational irritants, the prevalence of nasal symptoms
was the highest. This additive effect of exposure to to-
bacco smoke and occupational irritants on chronic nasal
symptoms remained when data were stratified by phys-
ician diagnosed allergic rhinitis (Table 2).
The prevalence of physician diagnosed allergic rhinitis
was 27.9% in the whole study sample. It was reported by
26.9% of smokers, by 28.9% of ex-smokers and by 27.8%
of non-smokers (p = 0.072). In men, environmental to-
bacco smoke or occupational irritants did not associate
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with physician diagnosed allergic rhinitis. Among
women, however, 33.7% of those exposed to occupa-
tional irritants had physician diagnosed allergic rhinitis
compared with 26.1% among the non-exposed (p =
0.032). Also in women, if occupational exposure was
combined with environmental tobacco exposure the
prevalence increased from 26.1% in non-exposed to
41.3% among exposed (p = 0.024).
The prevalence of longstanding nasal symptoms was high
also in those responders who did not report physician diag-
nosed allergic rhinitis, as 30.8% of them reported chronic
rhinitis, 25% nasal congestion, and 21.4% runny nose.
Results of the multiple logistic regression analysis are
given in Table 3. Current smoking, without exposure to
occupational irritants, yielded an odds ratio (OR) 1.22
(95%CI 1.00–1.49) for chronic rhinitis, and 1.26 (95%CI
1.01–1.56) for nasal congestion. Exposure to environ-
mental tobacco smoke at home or at work did not, as
such, increase the risk significantly in our model due to
collinearity.
Occupational irritants were associated almost signifi-
cantly with chronic rhinitis OR 1.28 (95%CI 0.97–1.69),
with nasal congestion OR 1.20 (95%CI 0.90–1.60), and sig-
nificantly with runny nose OR 1.49 (95%CI 1.11–1.99).
Table 1 Age, gender, smoking, environmental tobacco smoke and occupational irritants of the studied population
All Men Women
N (%) 3488 1491(42.7%) 1997(57.3%)
Mean (SD) age, years 45.0(14.7) 45.3(14.4) 44.9(14.9)
Age 20–29 643(18.4%) 246(16.5%) 397(19.9%)
30–39 785(22.5%) 361(24.2%) 424(21.2%)
40–49 564(16.2%) 249(16.7%) 315(15.8%)
50–59 712(20.4%) 305(20.5%) 407(20.4%)
60–69 740(21.2%) 314(21.1%) 426(21.3%)
Smokers 929 (26.6%) 464(31.1%) 465(23.3%)
Ex-smokers 907(26.0%) 425(28.5%) 482(24.1%)
Non-smokers 1764(50.6%) 659(44.2%) 1105(55.3%)
Exposure to tobacco smoke at work 326(9.3%) 169(11.3%) 157(7.9%)
Exposure to tobacco smoke at home 358(10.3%) 170(11.4%) 188(9.4%)
Exposure to occupational irritants 934(26.8%) 479(32.1%) 455(22.8%)
Age, gender, smoking and exposure characteristics of the studied population. Occupational irritants = exposure to gases, dust or fumes at work. The figures
indicate the number of subjects except age groups indicated in years
Fig. 1 Prevalence of chronic rhinitis, nasal congestion and runny nose in different exposures and their combinations
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The risk was not further increased, if the responders were
also exposed to environmental tobacco smoke.
Current smoking combined with exposure to occupa-
tional irritants gave the highest risk estimates for nasal
symptoms: OR 1.80 (95%CI 1.39–2.33) for chronic rhin-
itis, 1.82 (95%CI 1.40–2.35) for nasal congestion, and
1.68 (95%CI 1.28–2.19) for runny nose.
Discussion
Current smoking in combination with occupational expos-
ure to gases, dusts or fumes resulted in increased occur-
rence of chronic nasal symptoms in both genders
suggesting an additive harmful effect. Smoking alone was
associated with chronic rhinitis and nasal congestion.
Occupational irritants were associated with runny nose in
both genders, and among women also with chronic rhinitis
and nasal congestion. The risk increase is modest but obvi-
ously becomes significant in large populations.
The prevalence of longstanding nasal symptoms was
high: 36.9% reported chronic rhinitis, 29.8% nasal con-
gestion, and 27.9% runny nose. These symptoms were
even more common than previously reported in Sweden
[20, 21], but comparable to recent studies from Finland
and Sweden [14, 18] .
We found exposure to occupational irritants to be a
significant risk factor for chronic nasal symptoms, which
is consistent with previous observations [20, 22, 23].
However, in a recent Swedish study occupational
Table 2 Prevalence of chronic rhinitis, nasal congestion and runny nose
Unexposed Smoker ETS at home ETS at work Occupatio-nal irritants ETS +
Occupational irritants
Smoker +
Occupational irritants
All responders
Chronic rhinitis 31.7% 36.1%
0.073
36.4%
0.29
44.3%
0.01
46.4%
0.000
45.9%
0.007
55.1%
0.000
Nasal congestion 24.9% 29.4%
0.049
30.6%
0.17
42.3%
0.000
40.1%
0.000
43.5%
0.000
49.1%
0.000
Runny nose 23.8% 25.2%
0.54
26.4%
0.51
25.8%
0.65
36.7%
0.000
32.9%
0.056
40.7%
0.000
Responders with physician diagnosed allergic rhinitis
Chronic rhinitis 51.4% 50.0%
0.77
54.1%
0.76
70.0%
0.051
66.7%
0.006
65.5%
0.14
69.6%
0.002
Nasal congestion 42.9% 43.0%
0.98
51.4%
0.33
66.7%
0.012
57.1%
0.010
65.5%
0.019
64.1%
0.000
Runny nose 40.1% 39.2%
0.86
40.5%
0.96
46.7%
0.48
59.0%
0.001
48.3%
0.39
53.3%
0.023
Responders without physician diagnosed allergic rhinitis
Chronic rhinitis 24.3% 31.1%
0.008
28.6%
0.39
32.8%
0.12
37.7%
0.000
35.7%
0.056
49.6%
0.000
Nasal congestion 18.2% 24.5%
0.007
21.4%
0.47
31.3%
0.008
32.8%
0.000
32.1%
0.010
43.4%
0.000
Runny nose 17.7% 20.1%
0.28
20.2%
0.56
16.4%
0.79
27.0%
0.001
25.0%
0.17
36.0%
0.000
Prevalence of chronic rhinitis, nasal congestion and runny nose stratified according to risk factors: smoking, environmental tobacco smoke (ETS), occupational
irritants, or their combinations among all responders and among responders with and without physician diagnosed allergic rhinitis. Probability figures are
indicated below each prevalence figure. p-values are given between unexposed and those, who are exposed to one or more of the risk factors
Table 3 Risk factors for long-term nasal symptoms in a multiple logistic regression model
Chronic rhinitis Nasal congestion Runny nose Physician diagnosed
allergic rhinitis
Unexposed 1 1 1 1
Smoker 1.22(1.00–1.49) 1.26(1.01–1.56) 1.08(0.86–1.36) 0.98(0.78–1.21)
ETS at home 0.75(0.49–1.14) 0.70(0.45–1.09) 0.75(0.47–1.21) 1.09(0.90–1.33)
ETS at work 0.99(0.58–1.73) 1.12(0.64–1.95) 0.57(0.30–1.09) 1.00(0.64–1.56)
Occupational irritants 1.28(0.97–1.69) 1.20(0.90–1.60) 1.49(1.11–1.99) 1.00(0.74–1.36)
ETS + occupational irritants 1.11(0.57–2.16) 1.31(0.66–2.58) 1.34(0.64–2.81) 1.37(0.67–2.78)
Smoker + occupational irritants 1.80(1.39–2.33) 1.82(1.40–2.35) 1.68(1.28–2.19) 0.94(0.71–1.25)
The figures indicate odds ratios (CI 95%). ETS Environmental tobacco smoke
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exposure to gases, dust or fumes was not associated with
current rhinitis [18]. As their definition of current rhin-
itis included individuals with allergic rhinitis or chronic
nasal symptoms, the results are not fully comparable.
Chronic nasal symptoms were more frequent among
smokers and ex-smokers in the whole study group as
found also in Sweden [20, 21] In the earlier report from
FinEsS studies from 1997 to 2003, smoking was not as-
sociated with rhinitis symptoms [14]. In that report,
however, the definition of rhinitis symptoms included
also individuals with self-reported allergic rhinitis, which
may explain the difference. In a study from Vietnam,
using the same FinEsS-questionnaire, smoking was not a
risk factor for nasal symptoms [24]. The results may be
confounded by the much higher exposure to air pollu-
tion in Vietnam.
In our study, the prevalence of physician diagnosed al-
lergic rhinitis was the same among non-smokers (27.1%)
compared to current smokers (26.6%). Current smoking
did not either increase the prevalence of nasal symptoms
in those with physician diagnosed allergic rhinitis. How-
ever, smoking was associated with chronic nasal symp-
toms in the whole study sample, and increased the risk of
nasal congestion significantly among those without phys-
ician diagnosed allergic rhinitis (p = 0.007). Our findings
are in line with previous findings from U.S. [25] and sug-
gest that the association between nasal symptoms and to-
bacco exposure might be independent of allergy.
The possible association between tobacco smoke and al-
lergy has been studied previously. Smoking has been asso-
ciated with an increased risk of allergic disease [26, 27]
There is also evidence that tobacco smoke exposure would
prevent from allergic sensitization [25, 28]. In a study
from The Netherlands Vonk et al. [29] found that prenatal
smoke exposure was associated with a decreased risk for
the development of atopy. In another study from Canada
Hancox et al. present that personal and parental smoking
is associated with a lower risk of allergic sensitization in
people with a family history of atopy [30]. In our study the
prevalence of allergic rhinitis was independent of the
smoking status.
Environmental tobacco smoke is known to be a mod-
est risk factor for chronic nasal symptoms. Our results
are in accordance with earlier findings [14] This associ-
ation has also been confirmed in children [31]. We ob-
served that environmental tobacco smoke both at home
and at work slightly increased the occurrence of chronic
nasal symptoms, which is in line with previous observa-
tions [32]. Environmental tobacco smoke has also pre-
disposed to sinusitis [16].
In our study, exposure to environmental tobacco smoke
at home did not increase the prevalence of chronic nasal
symptoms in responders with or without physician diag-
nosed allergic rhinitis. Our findings are in line with
previous results from Estonia; Larsson et al. found no sig-
nificant association between ETS exposure at home and
respiratory symptoms [33]. It is likely that our study group
includes individuals that have been exposed to ETS at
home in the past as smoking inside is not as common
anymore as it has been in previous decades. Family mem-
bers may also quit or reduce smoking inside the home
more easily if one in their family develops respiratory
symptoms. The lack of association might at least partly be
explained by these mechanisms.
Responders who have been exposed to environmental
tobacco smoke at work reported to have nasal conges-
tion significantly more often in both groups. However,
second hand smoke neither at home nor at work was a
significant risk factor in our logistic regression model.
Our results are in agreement with a study from
Switzerland showing that second hand smoke was not
independently associated with rhinitis symptoms [33].
We have found earlier, that smoking and occupational
irritants have an additive effect on the incidence of
COPD [19]. In the present study, we suggest that this
additive exposure is also a risk factor for chronic nasal
symptoms. The combined effect was seen in all age
groups and whether or not allergic rhinitis was present.
Non-allergic rhinitis is divided into several subgroups.
Half of the patients with non-allergic rhinitis does not have
a clear etiology for their symptoms (e.g. occupational, hor-
monal, drug-induced) and are sometimes classified as
having an idiopathic rhinitis [2]. Our results suggest that
these symptoms are, at least partly, explained by smoking,
environmental tobacco smoke or exposure to occupational
irritants. These risks are preventable by anti-smoking ef-
forts and reduction of occupational exposure.
Study limitations
The observations are derived from a questionnaire sur-
vey based on a random population sample with a partici-
pation rate of 51%. With two reminders, we find the
representativeness satisfactory. Participation rates have
decreased by time in epidemiological studies which is a
general problem. The response rate has been about the
same in other epidemiological studies as in our study,
for example 55% in Copenhagen City Heart Study. [34]
and 53% in a Swedish follow up study on the prevalence
of asthma [35].
The FinEsS questionnaire has been used in several other
studies. Some new questions of nasal symptoms were
added, which improved the detection of the nasal condi-
tions. An obvious limitation of the present survey is the
lack of individual clinical evaluation of the responders.
We did not take into account ambient air pollution, which
could potentially confound our findings. However, in
Finland air pollution is minimal and well controlled, even
in cities.
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Conclusions
In conclusion, smoking, environmental tobacco smoke
and occupational exposure to gases, dusts or fumes in-
crease significantly the prevalence of chronic nasal symp-
toms both in men and women. The combined effect of
smoking and occupational exposure was the most marked
risk factor yielding the highest prevalence estimates. Thus,
anti-smoking efforts at population level and measures to
stop smoking and irritant exposure at work may reduce
nasal symptoms. The campaign for Tobacco-Free Finland
at 2030 [30] and the Healthy Workplaces Campaign [31]
have been launched and should be strongly promoted.
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